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Abstract
Aims Prolonged QT interval is associated with cardiac
arrhythmias and sudden death. The present study deter-
mined the prevalence of prolonged QT interval and QT
dispersion and defined their clinical and metabolic pre-
dictors in patients with type 2 diabetes.
Methods Cross-sectional study included 501 patients with
type 2 diabetes. A standard 12-lead electrocardiogram was
recorded. QT corrected for heart rate (QTc)[440 ms and
QT dispersion (QTd)[80 ms were considered abnormally
prolonged. QTc C 500 ms was considered a high-risk QTc
prolongation. Demographic, clinical and laboratory data
were collected. Independent risk factors for prolonged QTc
and QTd were assessed using logistic regression analysis.
Results Prevalence of QTc[ 440 ms and QTd[ 80 ms
were 44.1 and 3.6 %, respectively. Prevalence of high-risk
QTc (C500 ms) was 2 % only. Independent risk factors for
QTc prolongation [440 ms were mean blood glucose
(b = 2.192, p\ 0.001), treatment with sulphonylurea
(b = 5.198, p = 0.027), female gender (b = 8.844,
p\ 0.001), and coronary heart disease (b = 8.636,
p = 0.001). Independent risk factors for QTc C 500 ms
were coronary heart disease (b = 4.134, p\ 0.001) and
mean blood glucose level (b = 1.735, p\ 0.001). The
independent risk factor for prolonged QTd was only
coronary heart disease (b = 5.354, p\ 0.001).
Conclusions Although the prevalence of prolonged
QTc[ 440 ms is significant, the prevalence of high-risk
QTc (C500 ms) and QTd[ 80 ms is very low in patients
with type 2 diabetes. Hyperglycaemia and coronary heart
disease are strong predictors of high-risk QTc.
Keywords Type 2 diabetes  ECG  QT interval  QT
dispersion
Introduction
The QT interval in the surface electrocardiogram (ECG)
reflects the total duration of depolarization and repolar-
ization of the ventricles. QT dispersion (QTd) represents
nonuniformity of regional myocardial ventricular repolar-
ization and is reflected by differences of the QT interval
duration between ECG leads. Both prolonged QT interval
and prolonged QTd form a substrate for malignant ven-
tricular arrhythmias. Previous studies showed that a
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prolonged QT interval and QT dispersion are predictors of
cardiovascular mortality and all-cause mortality in patients
after acute myocardial infarction [1], patients with heart
failure [2], patients with diabetes type 1 and 2 [3, 4],
patients with idiopathic long QT syndrome [5] and in the
population of apparently healthy individuals [6, 7].
The aims of this study were to determine the prevalence
of prolonged QT interval and QT dispersion in patients
with type 2 diabetes and their correlations with clinical and
metabolic parameters, with particular emphasis on coro-
nary heart disease, the parameters of glycaemic control and
type of diabetes treatment.
Methods
Study design and patients
This cross-sectional study included 501 Caucasian patients
with type 2 diabetes (277 men) treated at the National
Educational Centre and Hospital for Diabetes, ‘‘Merkur’’
Vrnjacˇka Banja, Serbia, from September 2011 until
December 2012. Study was approved by the local research
committee and all the procedures were according to Dec-
laration of Helsinki and all study participants provided
written informed consent. The mean age (SD) was 60.4
(8.1) years, and the mean duration of diabetes (SD) was 9.9
(6.8) years.
Type 2 diabetes was defined as a diagnosis made after
39 years of life with the lack of need for insulin treatment
within the first year after diagnosis. Hypertension was
defined as systolic blood pressure [140 mmHg and/or
diastolic blood pressure[90 mmHg during C2 measure-
ments, or current antihypertensive therapy. Retinopathy
was assessed by retinal photographs centrally graded by a
single observer. Distal symmetric neuropathy was diag-
nosed according to the EMNG findings, or relevant signs
and symptoms including determination of vibratory per-
ception threshold. Coronary heart disease was defined as
the history of previous myocardial infarction, unsta-
ble angina, coronary artery bypass grafting, percutaneous
coronary intervention, positive findings on coronary
angiography, positive ECG stress test, typical effort angina,
or Minnesota code 1.1 or 1.2 in a surface ECG [8].
Estimated glomerular filtration rate (eGFR) was calcu-
lated according to serum creatinine level using the MDRD
formula [9].
All patients were free of clinical signs of the existence
of cardiovascular autonomic neuropathy (i.e. orthostatic
hypotension). The study excluded patients with ECG signs
of myocardial hypertrophy, bundle branch block, as well as
patients on treatment with drugs known to affect the QT
interval, especially antiarrhythmic class I and III, digitalis,
and antidepressants.
QT interval length and QT dispersion
In a standard ECG (Schiller AT1, Cardiovit, Switzerland),
recorded in a supine position, RR and QT intervals were
measured by two independent observers, who were blinded
to patients’ data, using a ruler and magnifying glass. QT
interval was measured from the beginning of QRS complex
to the end of the T wave in the intersection with the iso-
electric line [10]. QT corrected for the length of the pre-
vious cycle (QTc) was obtained using Bazett’s formulae:
QTc = QT/HRR (sec) [11].
QTc is the mean of QTc from five consecutive cycles in
lead V5. QTc[ 440 ms was considered abnormally pro-
longed, whereas QTc C 500 ms was considered high-risk
QT prolongation. RR and QT intervals were also measured
in three consecutive cycles in each of the six thoracic lead.
QTc dispersion (QTd) was calculated as the difference
between the maximum and minimum QTc at any thoracic
lead. QTd[ 80 ms was considered an abnormally pro-
longed [12].
For each patient the values of QTc and QTd represent
average values of the readings of the two observers. ECG
recordings were performed on the same day as daily gly-
caemia profile.
Parameters of glycaemic control
After hospitalization, the patients were put on a dietary
regimen. For each patient calorie intake was calculated
based on ideal body weight (IBW) and estimates of daily
calorie consumption (25–30 kcal/IBW). The composition
of the meal was carbohydrates 60 %, protein 20 % and fat
20 %. Meals were taken at 7:30 AM, 12:00 AM and 6:00
PM. On the second day of admission, glycaemic daily
profile was determined for each patient. Glucose levels
were determined from capillary blood sample using the
glucose hexokinase assay (EKF Diagnostics, Germany). In
patients treated with oral hypoglycaemic agents, daily
profile consists of six capillary blood glucose values: three
before each main meal (at 7:30 AM, 12:00 AM, and 6:00
PM) and three 2 h after the main meal (at 10:00 AM, 2:30
PM and 8:30 PM). In patients who received insulin, daily
glycaemia profile included two additional blood samples
taken at 12:00 midnight and 3:00 AM, giving a total of 8
values. From the analysis were excluded patients with
hypoglycaemic values in daily glycaemia profile, due to
potential influence of reflex sympathetic stimulation on the
length of the QT interval. Hypoglycaemia was defined as
glucose levels\3.9 mmol/L (70 mg/dL).
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The following parameters of glycaemic control were
used: fasting blood glucose (FBG), the mean postprandial
glucose, the mean blood glucose (MBG), the mean
amplitude of glycaemic excursion (MAGE) and glycated
haemoglobin A1c (HbA1c). To assess glycaemic fluctua-
tions during the day, we used the MAGE, described by the
Service et al. [13]. It is calculated as the arithmetic mean of
the absolute differences of the peak and subsequent nadir
of blood glucose values in daily glycaemia profile, wherein
in calculation are taken only differences[1 SD of the mean
glycaemia value. The MAGE is an independent measure of
mean blood glucose value designed to evaluate daily
fluctuations in blood glucose. A significant relationship
was previously demonstrated between such model of dis-
continuous glucose sampling and model of continuous
subcutaneous glucose monitoring [14]. All laboratory data
were centrally collected and patients’ screening was per-
formed during hospitalization period with the same
instrument and observer.
Statistical analysis
All statistical analysiswas carried out usingSPSSversion21.0
(SPSS Inc.Chicago, IL). Prior to statistical analysis, datawere
checked for univariate and multivariate outliers using stan-
dard Z-distribution cut-offs and Mahalanobis distance tests.
Normality of distribution was assessed using a Kolmogorov–
Smirnov test. Differences in clinical characteristics of patients
between subgroups of QTc (B440 or[440 ms duration) and
QTc dispersion (B80or[80 ms)were assessed using the t test
for continuous variables as appropriate; results are shown as
mean ± standard deviation (SD). Differences between cate-
gorical variables were assessed using Chi-squared test. To
assess variables that were independently predictive of pro-
longed QTc duration and QTc dispersion, we used logistic
regression analysis. Variables entered into initial model were
age, sex, diabetes duration, body mass index, systolic and
diastolic blood pressure, coronary heart disease, stroke,
retinopathy, polyneuropathy, diabetes therapy (metformin,
sulphonylurea, insulin), fasting glucose, mean postprandial
glucose, mean blood glucose, MAGE, HbA1c, total choles-
terol, triglycerides, and estimated glomerular filtration rate.
Variables were retained in the final model if they added sig-
nificantly to the likelihood of models or to the estimated
coefficients of predictors. Statistical significance was indi-
cated if p\ 0.05.
Results
Patients’ demographic, clinical and metabolic data are
presented in Table 1. Prevalence of prolonged QTc dura-
tion and QTc dispersion in patients with type 2 diabetes
were 44.1 and 3.6 %. Additionally, 2 % of patients
demonstrated prolonged QTc interval of C500 ms. QTc
duration and dispersion were affected by the gender with
females demonstrating significantly higher prevalence of
prolonged QTc duration (both [440 and [500 ms) than
men (55 vs 36 %, and 4 vs 1 %, p\ 0.05) and QTc dis-
persion (5 vs 3 %, p\ 0.05; Table 2).
Patients with prolonged QTc interval had significantly
higher age (p\ 0.02), body mass index (p\ 0.01), and
prevalence of coronary heart disease (p\ 0.01), retinopa-
thy (p\ 0.01), polyneuropathy (p\ 0.01), and the use of
sulphonylurea (p\ 0.01; Table 3). Measures of metabolic
control, i.e. HbA1c, daily glucose fluctuation (MAGE),
mean blood glucose, fasting blood glucose, mean post-
prandial glucose and triglycerides, were significantly
higher in patients with QTc interval duration of[440 ms
(p\ 0.05; Table 3). Patients with prolonged QTd showed
significantly higher age and prevalence of coronary artery
disease.
There was a significant moderate relationship between
the QTc duration and QTc dispersion (r = 0.36,
p\ 0.001). However, 50 % of patients with a normal QT
interval dispersion (\80 ms) showed an increased QTc
interval duration ([440 ms).
Table 1 Patients demographic, clinical and metabolic characteristics
Total number of patients 501
Gender (male/female) 277/224
Age (years) 60.4 ± 8.1
Diabetes duration (years) 9.9 ± 6.9
Body mass index (kg/m2) 30.4 ± 4.8
Systolic blood pressure (mmHg) 136.7 ± 48.7
Diastolic blood pressure (mmHg) 80.8 ± 7.0
Coronary heart disease (%) 22.9
Stroke (%) 6.8
Retinopathy (%) 47.5
Polyneuropathy (%) 74.5
Metformin (%) 77.2
Sulphonylurea (%) 38.5
Insulin (%) 69.1
Fasting glucose (mmol/l) 8.9 ± 2.9
Mean postprandial glucose (mmol/l) 10.4 ± 3.5
Mean blood glucose (mmol/l) 9.3 ± 3.0
MAGE (mmol/l) 4.1 ± 2.1
HbA1c (%) 8.1 ± 1.4
Total cholesterol (mmol/l) 5.8 ± 1.5
Triglycerides (mmol/l) 2.1 ± 1.6
eGFR (ml/min/1.73 m2) 96.4 ± 22.7
MAGE mean amplitude of glycaemic excursion, eGFR estimated
glomerular filtration rate
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In multivariate logistic regression analyses and after
adjustment for age and gender, the independent predictors of
prolongedQTc intervalweremeanblood glucose (b = 2.192,
p\ 0.001), female gender (b = 8.844, p\ 0.001), coronary
artery disease (b = 8.636, p = 0.001), and treatment with
sulphonylurea (b = 5.198, p = 0.027; Table 4). On the other
note, only coronary heart disease was independent predictor a
prolonged QTc dispersion (b = 5.354, p\ 0.001), adjusted
for age and gender. Finally, the independent predictors of
increased QTc duration of C500 ms were coronary heart
disease (b = 4.134, p\ 0.001) andmean blood glucose level
(b = 1.735, p\ 0.001).
Discussion
In our population of patients with type 2 diabetes, the
prevalence of QTc[ 440 ms is relatively high and
accounts to 44.1 %. However, the prevalence of high-risk
QTc C 500 ms is only 2 %. It has been shown in patients
with congenital and acquired long QT syndrome that
malignant arrhythmias are most often associated with val-
ues of 500 ms or more [15–18]. Our data show that the
largest proportion of patients with prolonged QTc is in the
‘‘grey zone’’ between arbitrarily taken value of 440 and
500 ms, and that the percentage of patients with a real risk
Table 2 Prevalence of
increased QTc interval duration
and QTc dispersion in patients
with type 2 diabetes
Males (n = 277) Females (n = 224) Total (n = 501)
Increased QTc duration ([440 ms) 35.7 (28.2–39.1) 54.5 (46.0–61.2)* 44.1 (39.6–52.4)
Increased QTc duration (C500 ms) 0.7 (0.4–1.1) 3.5 (2.7–4.6)* 2.0 (1.6–2.4)
Increased QTc dispersion ([80 ms) 2.9 (2.3–3.3) 4.5 (3.7–5.1)* 3.6 (3.0–4.1)
Values are given as % (95 % CI)
QTc QT interval corrected for heart rate, CI confidence interval
* Significantly higher than Males (p\ 0.05)
Table 3 Demographic, clinical and metabolic characteristics of patients with type 2 diabetes by QTc duration and QTc dispersion
QTc duration QTc dispersion
\440 ms [440 ms p \80 ms [80 ms p
(n = 280) (n = 221) (n = 483) (n = 18)
Age (years) 59.6 ± 8.0 61.4 ± 8.1 0.017 60.2 ± 8.1 64.8 ± 7.7 0.023
Diabetes duration (years) 9.5 ± 6.8 10.3 ± 6.7 0.205 9.8 ± 6.5 11.5 ± 6.4 0.298
Body mass index (kg/m2) 29.9 ± 4.5 31.1 ± 5.2 0.005 30.4 ± 4.9 30.3 ± 3.7 0.921
Systolic blood pressure (mmHg) 135.9 ± 63.2 137.6 ± 17.3 0.665 136.8 ± 49.5 133.6 ± 17.1 0.497
Diastolic blood pressure (mmHg) 80.4 ± 6.5 81.4 ± 7.6 0.140 80.9 ± 7.0 79.4 ± 6.6 0.379
Coronary heart disease (%) 15.4 33.1 <0.001 21.3 66.7 0.001
Stroke (%) 5.1 7.7 0.520 5.6 5.3 0.969
Retinopathy (%) 35.4 57.6 0.002 32.5 38.4 0.815
Polyneuropathy (%) 68.6 80.1 0.005 72.7 77.5 0.699
Metformin (%) 77.5 76.9 0.879 77.2 77.9 0.985
Sulphonylurea (%) 33.2 45.2 0.006 38.3 44.9 0.622
Insulin (%) 71.1 66.5 0.277 68.9 72.4 0.770
Fasting glucose (mmol/l) 8.3 ± 2.3 9.6 ± 3.3 <0.001 8.9 ± 2.9 8.3 ± 2.1 0.305
Mean postprandial glucose (mmol/l) 9.5 ± 2.7 11.5 ± 4.1 <0.001 10.4 ± 3.5 10.5 ± 2.9 0.814
Mean blood glucose (mmol/l) 8.5 ± 2.2 10.3 ± 3.6 <0.001 9.2 ± 3.1 9.5 ± 2.7 0.741
MAGE (mmol/l) 3.8 ± 1.8 4.4 ± 2.3 0.004 4.1 ± 2.0 4.9 ± 2.8 0.267
HbA1c (%) 7.9 ± 1.3 8.3 ± 1.4 0.001 8.1 ± 1.4 8.0 ± 1.0 0.822
Total cholesterol (mmol/l) 5.6 ± 1.6 5.7 ± 1.4 0.706 5.7 ± 1.5 4.9 ± 1.1 0.380
Triglycerides (mmol/l) 2.0 ± 1.0 2.3 ± 2.1 0.022 2.1 ± 1.6 2.0 ± 0.7 0.605
eGFR (ml/min/1.73 m2) 94.9 ± 24.6 98.2 ± 30.9 0.461 97.1 ± 20.0 75.7 ± 44.5 0.346
p\ 0.05 denotes statistical significance
MAGE mean amplitude of glycaemic excursion, eGFR estimated glomerular filtration rate
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of malignant arrhythmias is low (2 %). The prevalence of
pathological QTd ([80 ms) is also low (3.6 %).
These findings are important as they demonstrate that
the prevalence of highly prolonged QTc and QTd, which
can be associated with severe arrhythmias, is low in
patients with type 2 diabetes. From our clinical practice we
know that sudden death due to life-threatening arrhythmias
in patients with type 2 diabetes is not very common.
Sudden death is rather caused by acute cardiovascular
events, i.e. myocardial infarction and stroke. Coronary
artery disease and poor metabolic control are often the
triggers of high-risk QTc and sudden death.
Previous studies in patients with type 2 diabetes showed
that the prevalence of QTc and QTd is markedly different
and ranged from 15.4 to 67 % for QTc, and from none to
33 % for QTd [19–22]. Such large differences may result
from inaccurate identification of the beginning and the end
of the QT interval by the observer or the software in the
case of automatic analysis of ECG tracings, or the result of
selection bias. Furthermore, QTd differences are conse-
quence of different cut-off values in the definition of
pathological QTd (between 50 and 80 ms).
There are several risk factors connected with repolar-
ization disturbances in previous studies. Earlier studies
have suggested a relationship between diabetic cardiovas-
cular autonomic neuropathy (CAN) and QT prolongation.
Since the determination of CAN using classical cardio-
vascular tests is complicated [23], it has been proposed that
determination of QTc duration is specific and easier
methods for detection of CAN [24]. However, later studies
have not confirmed association of prolonged QT and CAN
in diabetes type 1 and 2 [25, 26]. Moreover, a large meta-
analysis that investigated the sensitivity and specificity of
prolonged QT interval for the detection of CAN in patients
with diabetes suggested that prolonged QT interval is a
poor indicator of CAN [27]. Previous studies have also not
demonstrated significant relationship between QTd and
autonomic dysfunction in diabetic patients [28].
Several other risk factors were indicated in prolonged
QT interval in diabetes, including systolic and diastolic
blood pressure [22, 29, 30], hyperglycaemia [22, 31],
serum insulin level [29, 32], microvascular diabetic com-
plication [22, 33] and coronary heart disease [20, 29]. As
risk factors for prolonged QTd in the literature are also
reported CAN [34], arterial hypertension [28], and coro-
nary heart disease [20, 35]. It has become clear that inde-
pendent risk factors for QTc and QTd prolongation in
patients with type 2 diabetes are different and depend
primarily on the set of variables tested.
Independent risk factors for QTc[ 440 ms in patients
with type 2 diabetes in our study group were: hypergly-
caemia, the use of sulphonylurea agents in the treatment of
diabetes, female gender and coronary heart disease. Inde-
pendent risk factors for QTc C 500 ms were only hyper-
glycaemia and coronary heart disease. Independent risk
factor for QTd[ 80 ms was coronary heart disease.
It was previously suggested that hyperglycaemia may
lead to QT prolongation through several mechanisms
including stimulation of protein kinase C leading to
reduced synthesis and release of endothelial derived nitric
oxide [36, 37]. This consequently lead to decrease in
activity of Na? K? ATPase, an enzyme responsible for
the maintenance of basal membrane potential of myo-
cytes, and cells of the conduction system (by maintaining
a high concentration of intracellular K and high concen-
tration of extracellular Na by mechanism of active
transport) [36, 37]. Reduced nitric oxide bioavailability
during hyperglycaemia is probably responsible for
decreased activity of Ca2? ATPase as well, an enzyme in
the membrane of myocytes that through active transport
mechanism maintains a low concentration of Ca2? ions in
the cell, resulting in an increase in the influx of Ca2? ions
during phase 2 of the action potential and extension of
QT interval [38].
Correlation between hyperglycaemia and QT interval
has been demonstrated in previous clinical studies includ-
ing patients with impaired glucose metabolism and in
apparently healthy individuals [22, 31, 39, 40]. Moreover,
in both clinical studies and experimental models, it has
been suggested that acute hyperglycaemia leads to pro-
longed QT interval not only in healthy subjects but also in
those with diabetes [41, 42].
Our results are in agreement with these suggestions,
given that the mean blood glucose derived from daily
glycaemia profile is independent risk factor for prolonged
QT interval, with a note that the daily profile of glycaemia
was determined the same day as the ECG recordings. On
the other hand, the relationship between glycaemia and
QTd has not been previously reported [28].
Table 4 Predictors of prolonged QTc interval and QTc dispersion in
patients with type 2 diabetes
b p
QTc duration[ 440 ms
Mean blood glucose 2.192 \0.001
Coronary artery disease 8.636 \0.001
Treatment with sulphonylurea 5.198 0.027
Female gender 8.844 \0.001
QTc duration[ 550 ms
Mean blood glucose 1.736 \0.001
Coronary artery disease 4.134 \0.001
QTc dispersion
Coronary artery disease 5.354 \0.001
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The effect of sulfonylurea agents on the incidence of
cardiovascular events in patients with diabetes is still
controversial. The closure of KATP channels in myocytes
under the influence of sulfonylurea leads to the depolar-
ization of the plasma cell membrane, opening of voltage-
dependent Ca2? channels with an increase in the influx of
Ca2? ions into the cell which generates a prolongation of
action potential during phase 2 of the action potential or
plateau phase. This results in a prolongation of the QT
interval in the ECG. The data in the literature on the
relationship between the treatment of diabetes with sul-
fonylureas and QT prolongation are scarce. In a small
group of subjects, Najeed and collaborators have found a
significant increase in QTc interval (and QT dispersion)
after 2 months of treatment with glibenclamide (from
433 ± 24 to 467 ± 24 ms), as opposed to patients
receiving treatment with metformin [43].
Influence of female gender on QT prolongation is well
established [33]. Normal adult women have longer QT
intervals than men, so widely accepted cut-off value for the
normal QTc interval is 440 ms for men and 460 ms for
women [44]. Moreover, as to heart rate dependence of the
QT interval, adult women have longer QT intervals at
longer cycle lengths than men [45]. However, electro-
physiological substrate for such gender differences is lar-
gely unknown.
During ischaemia, sympathetic hyperactivity accompa-
nied by an underlying myocardial structural damage is
likely to increase the ventricular repolarization duration
measured as QT interval on the body surface electrocar-
diogram. There is strong evidence suggesting the associa-
tion between QT abnormalities and acute and chronic
cardiac ischaemia [46, 47]. Moreover, QT prolongation and
QTd can be reduced by successful revascularization [48].
The underlying mechanism during acute ischaemia
responsible for the heterogeneity of repolarization (QTd)
could be identified on a cellular level as a decrease of the
resting membrane potential in the course of acute ischae-
mia, leading to a cellular uncoupling and a shortening of
the action potential duration [49].
In chronic ischaemic heart disease, QTd seems to rep-
resent the sum of several adverse cardiac abnormalities
such as fibrosis, hypertrophy, dilatation, ischaemia and
probably, autonomic dysfunction [50]. Obviously, QTd
could be considered as a non-invasive marker of potentially
lethal underlying cardiac abnormalities—the most impor-
tant being ischaemia. Our results are in accordance with the
findings of these studies and studies that have investigated
the association between cardiac ischaemia and repolariza-
tion disturbances in patients with type 2 diabetes [20, 29,
35].
Study limitations
The present study is not without limitations. The lack of
longitudinal data and follow-up patients’ clinical course
prevents generalization of the data and identification of
predictors associated with increased morbidity and mor-
tality in patients with type 2 diabetes, and in particular
development of potential life-threatening arrhythmias in
those with prolonged QTc interval. Only Caucasian
patients were included and prevalence and risk factors for
prolonged QTc interval and QT dispersion in patients with
other ethnic origins remains to be defined.
Conclusion
The prevalence of QT prolongation[440 ms is relatively
high (44.1 %), but the prevalence of high-risk QT pro-
longation (C500 ms), and QT dispersion [80 ms in
patients with type 2 diabetes is low (2 and 3.6 % respec-
tively). The use of sulfonylurea agents in the treatment of
diabetes and female gender are reasons for clinically
irrelevant QT prolongation in patients with type 2 diabetes.
Risk factors for high-risk prolonged QT interval
(C500 ms) are acute hyperglycaemia and history of coro-
nary heart disease. The independent risk factor for pro-
longed QT dispersion in type 2 diabetes is coronary heart
disease.
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